Table 2.
SDAI ≤ 3.3 and ≤ 11, CDAI ≤ 2.8 and ≤ 10, HAQ-DI ≥ 0.22 and DAS28-hsCRP ≤ 3.2 response rate
| Parameter | Week 12 | Week 24 | Week 52 | ||||
|---|---|---|---|---|---|---|---|
| Placebo (N = 115) n (%) |
BARI 4 mg (N = 116) n (%) |
p value | Placebo (N = 115) n (%) |
BARI 4 mg (N = 116) n (%) |
p value | BARI 4 mg (N = 116) n (%) |
|
| SDAI ≤ 3.3 | 0 | 1 (0.9) | 1.000 | 0 | 5 (4.3) | 0.060 | 7 (6.0) |
| SDAI ≤ 11 | 4 (3.5) | 19 (16.4) | 0.002 | 7 (6.1) | 28 (24.1) | 0.001 | 51 (44.0) |
| CDAI ≤ 2.8 | 0 | 1 (0.9) | 1.000 | 1 (0.9) | 4 (3.4) | 0.370 | 6 (5.2) |
| CDAI ≤ 10 | 5 (4.3) | 16 (13.8) | 0.016 | 6 (5.2) | 27 (23.3) | 0.001 | 51 (44.0) |
| HAQ-DI ≥ 0.22 | 66 (57.4) | 77 (66.4) | 0.153 | 38 (33.0) | 75 (64.7) | 0.001 | 72 (62.1) |
| DAS28-hsCRP ≤ 3.2 | 6 (5.2) | 26 (22.4) | 0.001 | 8 (7.0) | 38 (32.8) | 0.001 | 51 (44.0) |
BARI baricitinib, CDAI Clinical Disease Activity Index, DAS28-hsCRP Disease Activity Score 28-joint count, HAQ-DI Health Assessment Questionnaire—Disability Index, N number of Chinese modified intent-to-treat patients, n number of patients in the specified category, NA not applicable, SDAI Simplified Disease Activity Index